Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses

School of Public Health

1-1-2020

Patterns Of Care And Outcomes Of Patients With Myelofibrosis: A
Population-Based Study
Shelby Heath Meckstroth
meckssh0@sewanee.edu

Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl

Recommended Citation
Meckstroth, Shelby Heath, "Patterns Of Care And Outcomes Of Patients With Myelofibrosis: A PopulationBased Study" (2020). Public Health Theses. 1972.
https://elischolar.library.yale.edu/ysphtdl/1972

This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar –
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information,
please contact elischolar@yale.edu.

Patterns of Care and Outcomes of
Older Patients with Myelofibrosis:
A Population-based Study
Yale School of Public Health

Master of Public Health
Chronic Disease Epidemiology
May 2020

Author: Shelby Meckstroth
Committee:
First Reader: Dr. Xiaomei Ma
Second Reader: Dr. Nikolai Podoltsev
Third Reader: Dr. Rong Wang
1

Abstract
Background: Current treatments for Myelofibrosis (MF) are largely palliative, with ruxolitinib being
the breakthrough treatment approved for higher-risk patients by the Food and Drug Administration in
November of 2011. Little is known about the “real-world” patterns of care and outcomes of MF patients
since the introduction of ruxolitinib. Patients and Methods: The SEER-Medicare database was used to
identify older patients diagnosed with MF from 2007 through 2015. Treatment patterns were assessed
using Medicare part B and D claims, and multivariate cox proportional hazards regression models were
used to assess the effect of ruxolitinib use on survival in MF patients. Results: A total of 773 patients
were identified. The median age of our study population (N=773) was 76 years (IQR, 70, 80), and
88.9% of the population was non-Hispanic white. Of 342 patients who were diagnosed during 20122015 (i.e., the ruxolitinib era), 127 (37.1%) were ruxolitinib users. The median duration of ruxolitinib
use was 16.21 months. Most ruxolitinib users started with doses of 5 (23.6%), 10 (27.0%), or 20 (23.6%)
mg twice a day (BID). Among the patients who started treatment at 5 mg BID, 56.6% were never able to
increase the dose above 5 BID. Only 3.1% were able to use the maximum dose of 25 mg BID. 54.3% of
patients were taking hydroxyurea or prednisone during the same time period that they took ruxolitinib.
Medications to manage anemia were used more commonly by MF patients diagnosed before 2012.
Among patients diagnosed in 2012-2015, there was no difference in survival between ruxolitinib users
and non-users. Conclusion: Older MF patients treated with ruxolitinib had similar survival when
compared to patients who did not receive this medication but possibly belonged to the lower disease risk
group. For many ruxolitinib users, the dose of ruxolitinib could not be escalated, additional medications
were used concurrently, and the drug was discontinued quickly after initiation. Optimization of
ruxolitinib use may be necessary to accomplish better outcomes. Furthermore, development of new
drugs which may be used together with ruxolitinib or after its discontinuation is needed.
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Introduction
Myelofibrosis (MF) is a type of Philadelphia chromosome negative myeloproliferative neoplasm
(MPN), characterized by bone marrow fibrosis, systemic and splenomegaly-related symptoms,
cytopenias and abnormal extramedullary hematopoiesis (Barosi 1999, Cervantes et al. 2009). MF can be
primary or secondary when it develops after Polycythemia Vera (PV) or Essential Thrombocythemia
(ET). It is a rare disease with incidence of approximately 0.1 to 1 per 100,000 people per year (Moulard
et al. 2014). The median age of diagnosis is approximately 67 years, and the median survival is 3 to 7
years (Mesa et al. 1999, Kvasnicka et al. 2000). Arterial and venous thrombosis, the common feature in
MPNs, may occur among patients with MF with the rate of 0.95% to 1% patients per year (Guglielmelli
et al 2020).

There are a variety of treatments used to manage MF, however, most of them fall into the category of
supportive care. The only known disease-modifying treatment capable of curing MF is allogeneic
hematopoietic stem cell transplantation (allo HSCT) which, due to its high morbidity and mortality, is
reserved for younger patients who have higher-risk disease based on clinical and laboratory parameters
including cytogenetic and molecular data (Tefferi 2016). Other treatments are used to control diseaserelated symptoms including hydroxyurea, prednisone and spleen-directed therapies such as splenectomy
and splenic irradiation. Also, erythropoiesis-stimulating agents, androgens (e.g. danazol), and
immunomodulatory IMID drugs (IMIDs, with or without steroids) are used to improve anemia (Tefferi
2016).

Since the early 2000s, discovery of driver mutations and an improved understanding of the molecular
pathophysiology of MF have led to the development of new therapeutic approaches to this disease
(Wadleigh and Tefferi 2010). In November 2011, the United States Food and Drug Administration
5

(FDA) approved an oral JAK-inhibitor, ruxolitinib, for treatment of MF patients who are considered
intermediate- or high- risk based on the International Prognostic Scoring System (IPSS). This was based
on the results of two phase 3 randomized studies which showed significant reduction of spleen size and
improvement of symptoms among IPSS intermediate-2 and high-risk patients with MF when compared
to placebo (Verstovsek et al. 2012) and to best available therapy (Harrison et al. 2012). Ruxolitinib was
also shown in post-hoc analyses to improve overall survival (Mesa et al. 2014, Verstovsek 2012 and
Verstovsek 2015).

One of the common toxicities of ruxolitinib is worsening of anemia, and management is not well defined
in this setting. Some patients require short or long-term red blood cell transfusions and others utilize
anemia-directed therapies similar to non-ruxolitinib treated patients without good evidence to support
this approach (Barbui et al. 2018).
There are very limited data on the “real-world” clinical experiences and outcomes of patients with MF
who are treated in the JAK inhibitor era (Mascarenhas et al. 2020). MF became reportable to populationbased cancer registries such as the Surveillance, Epidemiology and End Results (SEER) program in
2001, making it possible to assess the incidence and survival of MF at the population level. Therefore,
the objective of this study is to understand the “real-world” patterns of care and outcomes of older adults
with MF since ruxolitinib became available for their management.

Methods
Data Source

The SEER-Medicare linked database, developed by the National Cancer Institute (NCI) and the Centers
for Medicare and Medicaid Services, links patient-level information from the SEER records with
6

Medicare enrollment and claims data. The SEER database contains 17 SEER regions, collects data on
survival and demographic information and covers approximately 34% of the United States population
(NCI 2019). The Medicare database includes data for inpatient, outpatient, physician services and
prescription drugs (Warren et al. 2002). Since the median age of MF diagnosis is 67 years old, the
SEER-Medicare database is a good data source to analyze the outcomes and treatment patterns of older
MF patients (Mesa et al. 1999). The most recent SEER-Medicare database includes MF patients
diagnosed between 2001 and 2015, with Medicare claims through the end of 2016. The Yale Human
Investigation Committee determined that this study did not directly involve human subjects.

Study Population

Since we needed to access Medicare Part D claims for the use of oral prescription drugs and Part D was
not available until 2006, we assembled a retrospective cohort of patients diagnosed with incident MF
(International Classification of Diseases for Oncology, Third Edition codes: 9961) between 2007 and
2015. All patients fulfilled the following eligibility criteria: 1) aged 66-99 years at diagnosis; 2) had
known month of diagnosis; 3) were not identified from death certificate or autopsy only; 4) had
continuous enrollment in Medicare Part D from diagnosis 5) had continuous enrollment in Medicare
Parts A, B and no enrollment in health maintenance organizations from 1 year before diagnosis until the
end of follow-up (death or 12/31/2016, whichever came first); and 6) bone marrow biopsy claim from 1
year before diagnosis to end of follow up.

Treatment Assessment

Prescription drug use was identified from the Medicare Part B and D claims using clinical modification
procedure codes (ICD-9 and ICD-10), the Healthcare Common Procedure Coding System (HCPCS)
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codes, and brand or generic name for oral drugs from Medicare claims. Prescription drug users were
defined as any patient that used the drug between the date of diagnosis and end of follow up. Allo
HSCT, splenectomy and splenic irradiation were assessed using ICD-9, ICD-10 and HCPCS codes.
Anemia drugs included: Darbepoeitin, Epogen, androgens [testosterone and danazol] and IMIDs
[lenalidomide and thalidomide].
The daily dose of ruxolitinib at initiation was assessed by using the patient’s first ruxolitinib prescription
via the formula [daily dose = (dose strength (mg)*quantity dispensed)/ number of days supplied]. We
calculated the end date of last dispense as dispense date plus number of days supplied, if the end date
exceeded the end of follow-up, we censored at the date of end of follow-up. Duration of ruxolitinib was
calculated as the difference between the first prescription date and end date of last dispense. We
restricted calculation of duration among patients with more than one ruxolitinib prescription. To
understand the use of concurrent drugs with ruxolitinib, we also assessed patients’ prescriptions on
prednisone and hydroxyurea within 1 month after ruxolitinib initiation and 1 month before
discontinuation of ruxolitinib, which was designated as the patient’s last prescription.

Outcome and Variable Assessment

Our primary outcome of interest was overall survival (OS). Patients were followed from the date of their
diagnosis until death or the end of the study period (December 31st, 2016), whichever came first.

We obtained information on the following patient characteristics: age at diagnosis, sex, race/ethnicity,
marital status, comorbidities, SEER region (West, South, Midwest, or Northeast) and census tract
median household income. To assess comorbidities, we used ICD-9 and ICD-10 diagnosis codes within
1 year prior to MF diagnosis in inpatient claims or at least 2 outpatient claims, 30 days apart. A modified
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Elixhauser score was developed previously by our research group by removing prior thrombosis from
the original Elixhauser score (Wang et al. 2017).

Statistical Analysis

Categorical variables were presented using frequencies and percentages. Continuous variables were
summarized by median and interquartile range (IQR). F-test for continuous variables and χ2 test for
categorical variables was used to compare treatment groups. Consistent with the SEER-Medicare
requirement to preserve confidentiality, all categories with ≤ 10 patients were reported as <11. KaplanMeier curves and log-rank tests were used to compare the incidence of death between treatment groups.
Multivariable Cox proportional hazards regression models with time dependent variables were used to
identify potential predictors of survival. A ruxolitinib user would only be considered as a user after the
initiation. Aside from treatments, we considered the possible influence of several patient characteristics
on OS, including age of diagnosis, sex, race/ethnicity, marital status, and comorbidities. All analyses
were conducted using SAS 9.4 (SAS Institute Inc., Cary, North Carolina) with two-sided tests and a type
I error of 0.05 as the threshold for statistical significance.

Results
Study Population and Baseline Characteristics

We identified a total of 773 patients who fulfilled the eligibility criteria. The median age at diagnosis
was 75 years (IQR, 70-80 years), 88.9% were non-Hispanic white, 55.1% were male, and 55.8% (N=
431) were diagnosed before 2012.
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Since ruxolitinib was approved to treat MF in November 2011, we further categorized our study
population into two groups: early era (diagnosed during 2007- 2011) and late era (diagnosed during
2012-2015). Patients diagnosed in the two eras were similar with respect to all characteristics except for
death at the end of the study period (p<0.001), comorbidities (p<0.001), SEER region (p=0.03) and
median household income (p<0.001) (Table 1).

The 342 patients who were diagnosed in the later era were further categorized into two groups based on
ruxolitinib use. A total of 127 (37.1%) patients ever used ruxolitinib after diagnosis. As shown in Table
2, there was no difference among any evaluated characteristics.

Treatment Patterns and Outcomes

To compare the pattern of treatment between the two eras, we censored the patients diagnosed in the
early era at the end of 2011. More patients diagnosed in the later era used hydroxyurea (39.2%) than
those diagnosed earlier (26.7%). However, more patients diagnosed in the early era used anemiadirected therapies (34.3% vs. 19.9%) and prednisone (36.2% vs. 30.1%) compared to those diagnosed
later (Figure 1).

Only a limited number (<11) of ruxolitinib users and non-users received splenic irradiation. There were
27 patients (7.9%) in the ruxolitinib era group who were 70 or younger at the time of MF diagnosis, and
out of these 27, less than 11 patients received allo HSCT.

The median time to initiation of ruxolitinib after MF diagnosis was 107 days (IQR, 47, 341.7 days,
N=127), and the majority of patients started at daily doses of 10, 20 or 40 milligrams (mg), which is 5,
10 and 20 mg per time twice a day (BID) (Figure 2). Of the 30 patients who started at 5 mg BID, 17
(56.7%) never had their dose of ruxolitinib escalated above 5 mg BID. Also, less than 11 patients were
10

able to go up to the highest dose of 25 mg BID. The median amount of time patients stayed on
ruxolitinib was 16.21 months (Figure 3). While on ruxolitinib treatment, 28 (22%) and 17 (13%) also
took hydroxyurea and prednisone, respectively. In addition, 12 (10%) ruxolitinib treated patients took
both hydroxyurea and prednisone during the same time period (Figure 4).

Ruxolitinib users had similar survival to non-user survival, with a median survival of 2.93 years in the
ruxolitinib treatment group and a median survival of 2.59 years in the non-ruxolitinib treatment group
(Figure 5). The percent of patients that died in each group was also similar: 48.84% died in the nonruxolitinib treatment group and 52% died in the ruxolitinib treatment group. In the multivariable
analysis, the risk of death among ruxolitinib users compared to non-users was not statistically significant
(p=0.33, Figure 5).

Discussion
In this retrospective population-based study that reflects real-world clinical practice, we assessed the
management of older patients diagnosed with MF in the real-world setting with a focus on the impact of
ruxolitinib, which was approved by the FDA in November 2011. Among patients diagnosed in 2012-15,
127 (37.1%) patients received ruxolitinib, with a median of 107 days to treatment initiation, and a
median duration of use of 16.21 months. About half of ruxolitinib users initiated treatment at low doses
(up to 10 mg BID). Although we did not observe any difference in survival between ruxolitinib users
and non-users, taking into consideration that ruxolitinib has been approved for higher risk MF patients,
our findings may imply that ruxolitinib could have had a positive effect on the outcomes of the treated
population.
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We found that lower initiation doses were common among older MF patients. Over half of ruxolitinib
users started at 5 or 10 mg BID, and only about 23% started at 20 mg BID, which is a maximal initiating
dose based on FDA approved drug prescription information (FDA 2019). The recommended dose at the
time of treatment initiation is based on patient’s platelet count: 20 mg, 15 mg and 5 mg BID for those
with platelets >200,000/mm3, 100,000 to 200,000/mm3, and 50,000 to <100,000/mm3, respectively
(FDA 2019). A dose of 5 mg BID is less effective than higher doses to accomplish symptom control and
decrease spleen size (Talpaz et al. 2013). However, 13.4% of ruxolitinib users in our study were never
prescribed a dose above 5 mg BID. This could be related to low platelet counts or concerns about side
effects, including anemia. Less than 11 (3.1%) patients were able to escalate their dosing to the highest
recommended dose of 25 mg BID, which should be considered if treatment results with lower doses are
unsatisfactory and if the patient is expected to tolerate dose escalation.
Many patients received both ruxolitinib and other symptom-directed therapies (including hydroxyurea
and/or steroids) at the same time, pointing to less than acceptable symptom control by ruxolitinib alone.
This could be related to lower doses of ruxolitinib being used by our patients. It is interesting that more
patients diagnosed after 2011 used hydroxyurea more than patients managed in the pre ruxolitinib era. A
more focused approach by providers to symptom control in ruxolitinib era can explain the wider use of
symptom-directed therapies. Even though ruxolitinib was added to management and hydroxyurea use
increased, anemia-directed drug therapies, expected to have higher demand in the setting of these
cytoreductive treatments, were used less frequently after 2011. This may be related to lack of evidence
behind concurrent use of these drugs with ruxolitinib, which is antagonistic to erythropoietin analogues
based on its mechanism of action.

As expected, very few patients in our cohort (N<11, 1.5%) received spleen-directed therapies before and
after introduction of ruxolitnib. Splenectomy is associated with high morbidity, including liver
12

enlargement and failure, thrombocytosis, thrombosis, intrabdominal infection and increased rate of blast
transformation as well as 30% perioperative morbidity and 10% mortality. Splenic irradiation is
associated with long-lasting cytopenias and transfusion dependence (Tefferi et al. 2000). The number of
cases receiving spleen-directed therapies is expected to decrease in the era of ruxolitinib due to its
successful ability to decrease spleen size, but we could not perform this analysis due to low frequency of
the above described procedures.

Even though allo HSCT is the only disease modifying treatment for MF, very few patients received
transplant in our study. Only 27 among 342 patients (7.9%) were transplanted. The average age of our
patient population was 76 years, which may explain infrequent allo HSCT use, as it is usually reserved
for younger (<70 years old) patients due to high procedure-related morbidity and mortality which
increases with age. Allo HSCT was not reimbursed by Medicare for MF patients until 2016, which may
be another reason for low prevalence of this treatment in our patient population.

Our study has several strengths. Its population-based design allowed us to evaluate real-world treatment
of older patients with MF and helped to assemble a large cohort of patients with this rare disease.
Limitations include short observation period as follow up duration could not exceed 5 years due to
ruxolitinib only being approved for MF patients since 2011. We also used Medicare claims to identify
treatments and procedures received by our patients. Therefore, any drugs or procedures not covered by
Medicare could not be factored into our analyses. As clinical and laboratory variables necessary to
estimate patients’ risk based on prognostic models utilized in clinical practice (IPSS) were not available,
we could not factor these risks into multivariable survival analysis. Also, the age of our population is
about 10 years older than the average age of MF patients at diagnosis which may lead to different
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outcomes among our patients when compared to the general population with this disease. Finally,
patterns of care might have been affected by a variety of unknown confounders.

Conclusion
This large population-based study of older patients with MF assessed their pattern of care in the
ruxolitinib era and showed similar survival of ruxolitinib users to non-users who are expected to have
lower risk disease. Ruxolitinib dose was not escalated above the lowest dose and to the highest
permitted dose in a large number of patients and treatment was discontinued quickly after initiation.
Optimization of ruxolitinib use may be necessary to accomplish better outcomes. Furthermore,
development of new drugs, which may be used with ruxolitinib or after its discontinuation, is needed.
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Appendix
Table 1. Characteristics of 773 older adults with MF, 2007-2015
Characteristic

Total
Race/ethnicity
Non-Hispanic
white
Other
Age at diagnosis
(years)
Median (IQR)
Sex
Male
Female
Marital status
Married
Unmarried
Unknown
Death at End of
Study Period
Yes
No
Comorbidities
0
1-2
3+
SEER Region
West
South
Midwest
Northeast
Census tract
median household
income
<33,000
33,000-40,000
40,000-50,000
>50,000

Overall
N (%)
773

Year of diagnosis
2007-2011
2012-2015
N (%)
N (%)
431
342

p†

0.20
687(88.9)

383(88.9)

304(88.9)

86(11.1)

48(11.1)

38(11.1)
0.31

76(70-80)

76(71-80)

75(70-80)
0.46

425(55.0)
348(45.0)

232(53.8)
199(46.2)

193(56.4)
149(43.6)
0.33

417(53.9)
258(33.4)
98(12.7)

233(54.1)
154(35.7)
44(10.2)

184(53.8)
104(30.4)
54(15.8)
<0.001

496(64.2)
277(35.8)

330(23.4)
101(76.6)

166(48.5)
176(51.5)
<0.001

211(27.3)
306(39.6)
256(33.1)

118(28.6)
175(40.6)
138(32.0)

93(27.2)
131(38.3)
118(34.5)

331(42.8)
149(19.3)
133(17.2)
160(20.7)

181(42.0)
81(18.8)
89(20.7)
80(18.7)

150(43.9)
68(19.9)
44(12.9)
80(23.4)

138(17.9)
56(7.2)
123(15.9)
456(59.0)

118(27.4)
29(6.7)
71(16.5)
213(49.4)

20(5.9)
27(7.9)
52(15.2)
243(71.1)

0.03

<0.001

* Numbers may not sum to totals due to missing data, and column percentages may not sum to 100% due to rounding.
†
P-value for analysis of variance F-test (continuous variable) or χ2 test (categorical variable).
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Table 2. Characteristics of 342 older adults with MF by ruxolitinib status, 2012-2015

Characteristic
Total
Race/ethnicity
Non-Hispanic
white
Other
Age at diagnosis
(years)
Median (IQR)
Sex
Male
Female
Marital status
Married
Not married
Unknown
Death at End of
Study Period
Yes
No
Comorbidities
0
1-2
≥3
SEER Region
West
South
Midwest
Northeast
Census tract
median household
income
<33,000
33,000-40,000
40,000-50,000
>50,000

Ruxolitinib
Ever
Never
N (%)
N (%)
127

p†

215
0.50

114(89.8)

190(88.4)

10(10.2)

25(11.6)
0.44

75(70-80)

75(70-80)
0.33

76(59.8)
51(40.2)

117(54.4)
98(45.6)

69(54.3)
38(29.9)
20(15.7)

115(53.5)
66(30.7)
34(15.8)

0.79

0.89
66(52.0)
61(48.0)

105(51.2)
110(48.8)
0.93

36(28.3)
48(37.8)
43(33.9)

57(26.5)
83(38.6)
75(34.9)
0.67

58(45.7)
23(18.1)
19(15.0)
27(21.3)

92(42.8)
45(20.9)
25(11.6)
53(24.7)
0.45

5(3.94)
11(8.66)
23(18.1)
88(69.3)

15(7.0)
16(7.4)
29(13.5)
155(72.1)

* Numbers may not sum to totals due to missing data, and column percentages may not sum to 100% due to rounding.
†
P-value for analysis of variance F-test (continuous variable) or χ2 test (categorical variable).
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45.00%
40.00%
35.00%
30.00%
25.00%

2007-2011

20.00%

2012-2015

15.00%
10.00%
5.00%
0.00%
Hydroxyurea

Ruxolitinib

Anemia
Drugs

Prednisone

*Censored patients after 2011 for patients diagnosed before 2012

Figure 1. MF related treatments among 773 older adults by era of diagnosis, 2007-2015

20 mg BID
N=30
23.6%

Other
N=11
8.7%
5 mg BID
N=30
23.6%

15 mg BID
N=21
16.5%
10 mg BID
N=35
27.6%

Figure 2. Daily ruxolitinib dose (BID) at treatment initiation (N=127)
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Percent of Patients on Ruxolitinib (N=108)
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72

33
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Figure 3. Duration of ruxolitinib treatment among 108 older adults with MF, 2012-2015

Hydroxyurea
(N=28)
22%

Neither Treatment
(N=70)
55%

Prednisone (N=17)
13%

Hydroxyurea and
Prednisone (N=12)
10%

Figure 4. Most commonly used concurrent drugs received by ruxolitinib treated patients (N=127;
treatments within one month after ruxolitinib initiation and one month before discontinuation)
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1.2

1
Ruxolitinib

Proportion Surviving

0.8

Other/ None

0.6

0.4

0.2

Log Rank Test: p= 0.33
0
0

1

2

3

4

5

6

Time (years)

N at risk at time point
Time (years)
1
Total
265
Other/None
156
Ruxolitinib
109

2
147
89
58

3
59
37
22

4
24
12
12

5
0
0
0

Treatment
Group

Total N

Died N (%)

Median
Survival

Unadjusted HR

Adjusted HR

Other/None

215

105(48.84)

2.59 yrs.

1

1

Ruxolitinib

127

66(52.00)

2.93 yrs.

0.86(0.62,1.17)

0.86(0.61,1.22)

* Adjusted for age, marital status, gender, comorbidities and race

Figure 5. Kaplan-Meier curves of survival among 342 older adults with MF by ruxolitinib status, 20122015
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